Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his ...

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and ...

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August ...

Find out what came out of the ESC Congress 2026, from phase 3 successes and failures to earlier-stage programs.

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science ...

The concept of targeted therapeutics is often traced back to German Nobel laureate Paul Ehrlich’s “magic bullet” in 1907, which envisioned a single entity that could both recognize a disease target ...

Discover six MASH companies to keep an eye on as the race to shape the next generation of liver disease therapies heats up.

In recent years, biopharma has paid significantly different prices for the same underlying technology. In March 2025, AstraZeneca agreed to pay EsoBiotec, an in vivo CAR-T platform with early ...

In biotech, tension in one of a company’s most consequential relationships usually becomes visible late. A partner hesitates. The board pushes back on terms everyone assumed were settled. A financing ...

Roughly half the people living with gout do not have treatments that work for them. While standards of care serve some of the population, many turn to calming gout flares with anti-inflammatory drugs ...

The biggest acquisition deal announced in June was by pharma giant AbbVie. Known for its monoclonal antibodies Humira and Skyrizi, for autoimmune diseases, AbbVie plans to buy Massachusetts-based ...